Scinai Immunotherapeutics Ltd. (SCNI) Earnings History
Annual and quarterly earnings data from 2009 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | -88.1% | -1312.8% | 728.9% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export SCNI earnings history in CSV or JSON format
Free sign-in required to download data
Scinai Immunotherapeutics Ltd. (SCNI) Earnings Overview
As of February 28, 2026, Scinai Immunotherapeutics Ltd. (SCNI) reported trailing twelve-month net income of $5M, reflecting +1.4% year-over-year growth. The company earned $2.90 per diluted share over the past four quarters, with a net profit margin of 7.3%.
Looking at the long-term picture, SCNI's historical earnings data spans multiple years. The company achieved its highest annual net income of $5M in fiscal 2024, representing a new all-time high.
Scinai Immunotherapeutics Ltd. maintains positive profitability with a gross margin of -0.9%, operating margin of -13.1%, and net margin of 7.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including BNTX (-$572M net income, -0.2% margin), MRNA (-$3.12B net income, -1.1% margin), SMMT (-$1.08B net income), SCNI has outperformed on profitability metrics. Compare SCNI vs BNTX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
16 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $5M | +173.8% | -$9M | $6.00 | 728.9% | -1312.8% |
| 2023 | -$7M | -12.1% | -$10M | $-16.80 | - | - |
| 2022 | -$6M | +29.4% | -$11M | $-30.80 | - | - |
| 2021 | -$8M | -492.1% | -$11M | $-80.00 | - | - |
| 2020 | -$1M | +95.6% | $2M | $-12.40 | - | - |
| 2019 | -$32M | -34.8% | -$23M | $-999999.00 | - | - |
| 2018 | -$23M | -136.2% | -$21M | $-999999.00 | - | - |
| 2017 | -$10M | -316.5% | -$7M | $-790280.00 | - | - |
| 2016 | -$2M | +8.9% | -$3M | $-282320.00 | - | - |
| 2015 | -$3M | -31.3% | -$3M | $-396880.00 | - | - |
See SCNI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SCNI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SCNI vs AGIO
See how SCNI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SCNI growing earnings?
SCNI EPS of $2.90 reflects slowing growth at +1.4%, below the 5-year CAGR of N/A. TTM net income is $5M. Expansion rate has moderated.
What are SCNI's profit margins?
Scinai Immunotherapeutics Ltd. net margin is +7.3%, with operating margin at -13.1%. Margins sit within typical range for the sector.
How consistent are SCNI's earnings?
SCNI earnings data spans 2009-2024. The current earnings trend is +1.4% YoY. Historical data enables comparison across business cycles.